CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-03-28 | Viret Jean-Frederic Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −400 | 134,573 | ||
| 2016-03-02 | Herman Alan C. Chief Scientific Officer | Sale | −6,015 | $15.32 | $92K | 215,115 |
| 2016-03-01 | Herman Alan C. Chief Scientific Officer | Sale | −485 | $15.00 | $7K | 221,130 |
| 2016-02-29 | Wahlstrom Mats Director | Purchase · 8.2% Senior Convertible Notes due 2022 | +1,000,000 | $22.35 | $22.4M | 1,000,000 |
| 2016-02-29 | Wahlstrom Mats Director | Purchase · 8.2% Senior Convertible Notes due 2022 | +0 | $22.35 | $0 | |
| 2016-02-29 | Troendle August J. Director | Purchase · 8.2% Senior Convertible Notes due 2022 | +0 | $22.35 | $0 | |
| 2016-02-09 | Troendle August J. Director | Option exercise | +8,124 | $0.42 | $3K | 29,994 |
| 2016-02-09 | Troendle August J. Director | Option exercise · Stock Option (Right to Buy) | −8,124 | 0 | ||
| 2016-02-05 | Herman Alan C. Chief Scientific Officer | Sale | −2,000 | $15.02 | $30K | 221,615 |
| 2016-01-04 | Herman Alan C. Chief Scientific Officer | Sale | −3,950 | $21.40 | $85K | 223,915 |
| 2016-01-04 | Herman Alan C. Chief Scientific Officer | Sale | −300 | $22.36 | $7K | 223,615 |
| 2015-12-23 | Herman Alan C. Chief Scientific Officer | Option exercise | +16,000 | $0.42 | $7K | 227,865 |
| 2015-12-23 | Herman Alan C. Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −16,000 | 32,862 | ||
| 2015-12-01 | Herman Alan C. Chief Scientific Officer | Option exercise | +8,499 | $0.42 | $4K | 223,198 |
| 2015-12-01 | Herman Alan C. Chief Scientific Officer | Sale | −2,400 | $28.80 | $69K | 220,798 |
| 2015-12-01 | Herman Alan C. Chief Scientific Officer | Sale | −8,933 | $29.67 | $265K | 211,865 |
| 2015-12-01 | Herman Alan C. Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −8,499 | 48,862 | ||
| 2015-11-30 | Lanfear Dennis M President and CEO | Sale | −400 | $31.75 | $13K | 1,344,526 |
| 2015-11-20 | Watler Peter K. Chief Technical Officer | Option exercise | +20,000 | $1.42 | $28K | 20,000 |
| 2015-11-20 | Watler Peter K. Chief Technical Officer | Sale | −20,000 | $27.41 | $548K | 0 |
Page 30 of 39 · 768 trades